Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Antipsychotic Discontinuation in Alzheimer's Disease

Authors not listed

New York State Psychiatric Institute · 2004

Abstract

In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then randomized, double-blind, to one of three arms in Phase B: (1) continuation risperidone for 32 weeks, (2) risperidone for 16 weeks followed by placebo for 16 weeks, (3) placebo for 32 weeks. The primary outcome is time to relapse of psychosis/agitation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (2004). Antipsychotic Discontinuation in Alzheimer's Disease. <em>New York State Psychiatric Institute</em>. https://clinicaltrials.gov/study/NCT00417482
Vancouver
Anonymous. Antipsychotic Discontinuation in Alzheimer's Disease. New York State Psychiatric Institute. 2004.
BibTeX
@misc{anon2004Antips, title = {Antipsychotic Discontinuation in Alzheimer's Disease}, author = {Anonymous}, journal = {New York State Psychiatric Institute}, year = {2004}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings